Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Plasmodium falciparum | glutathione reductase | Curated by TDR Targets | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | dihydrolipoyl dehydrogenase, apicoplast | glutathione reductase | 500 aa | 561 aa | 24.4 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | thioredoxin reductase, putative | 0.0076 | 0.2886 | 0.5 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0076 | 0.2886 | 0.2886 |
Loa Loa (eye worm) | hypothetical protein | 0.0148 | 1 | 1 |
Plasmodium vivax | glutathione reductase, putative | 0.0076 | 0.2886 | 0.5 |
Brugia malayi | Thioredoxin reductase | 0.0076 | 0.2886 | 0.2886 |
Toxoplasma gondii | thioredoxin reductase | 0.0076 | 0.2886 | 0.5 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0076 | 0.2886 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0148 | 1 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0076 | 0.2886 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0101 | 0.5371 | 0.5371 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0101 | 0.5371 | 0.5371 |
Plasmodium falciparum | glutathione reductase | 0.0076 | 0.2886 | 0.5 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0076 | 0.2886 | 1 |
Brugia malayi | glutathione reductase | 0.0076 | 0.2886 | 0.2886 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0148 | 1 | 1 |
Loa Loa (eye worm) | glutathione reductase | 0.0076 | 0.2886 | 0.2886 |
Plasmodium falciparum | thioredoxin reductase | 0.0076 | 0.2886 | 0.5 |
Leishmania major | trypanothione reductase | 0.0076 | 0.2886 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0101 | 0.5371 | 1 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0076 | 0.2886 | 0.5 |
Trypanosoma brucei | trypanothione reductase | 0.0076 | 0.2886 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 29 % | Analgesic activity in Wistar Albino mouse at 10 mg/kg, po after 3 hrs by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 29 % | Anti-inflammatory activity against carrageeenen-induced paw oedema rat model at 10 mg/kg after 3 hrs | ChEMBL. | 17079148 |
Activity (functional) | = 29 % | Analgesic activity in Wistar Albino mouse at 10 mg/kg, po after 3 hrs by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 31 % | Anti-inflammatory activity against carrageeenen-induced paw oedema rat model at 10 mg/kg after 30 mins | ChEMBL. | 17079148 |
Activity (functional) | = 33 % | Anti-inflammatory activity against carrageeenen-induced paw oedema rat model at 20 mg/kg after 3 hrs | ChEMBL. | 17079148 |
Activity (functional) | = 35 % | Anti-inflammatory activity against carrageeenen-induced paw oedema rat model at 10 mg/kg after 1 hr | ChEMBL. | 17079148 |
Activity (functional) | = 36 % | Analgesic activity in Wistar Albino mouse at 20 mg/kg, po after 3 hrs by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 36 % | Analgesic activity in Wistar Albino mouse at 20 mg/kg, po after 3 hrs by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 38 % | Analgesic activity in Wistar Albino mouse at 10 mg/kg, po after 30 mins by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 38 % | Anti-inflammatory activity against carrageeenen-induced paw oedema rat model at 10 mg/kg after 2 hrs | ChEMBL. | 17079148 |
Activity (functional) | = 38 % | Anti-inflammatory activity against carrageeenen-induced paw oedema rat model at 20 mg/kg after 30 min | ChEMBL. | 17079148 |
Activity (functional) | = 38 % | Analgesic activity in Wistar Albino mouse at 10 mg/kg, po after 30 mins by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 42 % | Anti-inflammatory activity against carrageeenen-induced paw oedema rat model at 20 mg/kg after 1 hr | ChEMBL. | 17079148 |
Activity (functional) | = 43 % | Analgesic activity in Wistar Albino mouse at 10 mg/kg, po after 1 hr by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 43 % | Analgesic activity in Wistar Albino mouse at 10 mg/kg, po after 2 hrs by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 43 % | Analgesic activity in Wistar Albino mouse at 10 mg/kg, po after 1 hr by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 43 % | Analgesic activity in Wistar Albino mouse at 10 mg/kg, po after 2 hrs by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 46 % | Anti-inflammatory activity against carrageeenen-induced paw oedema rat model at 20 mg/kg after 2 hrs | ChEMBL. | 17079148 |
Activity (functional) | = 50 % | Analgesic activity in Wistar Albino mouse at 20 mg/kg, po after 30 mins by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 50 % | Analgesic activity in Wistar Albino mouse at 20 mg/kg, po after 30 mins by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 53 % | Analgesic activity in Wistar Albino mouse at 20 mg/kg, po after 1 hr by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 53 % | Analgesic activity in Wistar Albino mouse at 20 mg/kg, po after 1 hr by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 57 % | Analgesic activity in Wistar Albino mouse at 20 mg/kg, po after 2 hrs by tail-flick technique | ChEMBL. | 17079148 |
Activity (functional) | = 57 % | Analgesic activity in Wistar Albino mouse at 20 mg/kg, po after 2 hrs by tail-flick technique | ChEMBL. | 17079148 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.